又有上市公司财务造假被严查

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. (ST Wuzhong) is facing potential forced delisting due to continuous financial fraud over four years, with the China Securities Regulatory Commission (CSRC) proposing a fine of 10 million yuan and indicating a "zero tolerance" stance towards such violations [1][5]. Group 1: Financial Misconduct - ST Wuzhong has been found to have falsified financial reports from 2020 to 2023, inflating revenue by 4.95 billion yuan, 4.69 billion yuan, 4.31 billion yuan, and 3.77 billion yuan, which accounted for 26.46%, 26.39%, 21.26%, and 16.82% of the reported revenue for those years respectively [2]. - The company also inflated total profits by 14.58 million yuan, 20.27 million yuan, 19.92 million yuan, and 21.22 million yuan, representing 2.89%, 51.65%, 26.42%, and 29.81% of the total profits for the respective years [2]. - Additionally, ST Wuzhong failed to disclose significant non-operating fund occupation by related parties, with amounts reaching 1.27 billion yuan, 1.39 billion yuan, 1.54 billion yuan, and 1.69 billion yuan from 2020 to 2023, which constituted 6.88%, 74.2%, 84.6%, and 96.09% of the net assets for those years [2]. Group 2: Regulatory Actions - The CSRC plans to impose a total fine of 30.5 million yuan on ST Wuzhong and its responsible individuals, with the actual controller, Qian Qunshan, facing a proposed 10-year ban from the securities market due to severe misconduct [3]. - Starting July 14, ST Wuzhong's stock will be subject to delisting risk warnings due to its financial fraud, which has already led to previous warnings and a lack of opinion from the auditing firm on its 2024 financial report [4]. - The company has expressed its intention to cooperate with the CSRC and will exercise its rights to defend against the proposed penalties [4].